Ascendis Pharma A/S (ASND)
Healthcare • Biotechnology
StockNasdaqGSDenmarkDK0060615755
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Ascendis Pharma A/S, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:30. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 07 May 2026 07:00 | -0.08 | 0.27 | +429.3% | Beat |
| 30 Apr 2026 16:00 | 0.43 | — | — | — |
| 11 Feb 2026 16:00 | -0.24 | -0.55 | -124.5% | Miss |
| 12 Nov 2025 16:00 | -0.12 | -1.00 | -740.1% | Miss |
| 07 Aug 2025 16:00 | -1.26 | -0.64 | +49.3% | Beat |
| 01 May 2025 16:00 | -1.51 | -1.58 | -5.0% | Miss |
| 12 Feb 2025 16:00 | -1.17 | -0.64 | +45.4% | Beat |
| 14 Nov 2024 16:00 | -1.46 | -1.72 | -18.1% | Miss |
| 03 Sep 2024 17:00 | -1.34 | -1.91 | -42.9% | Miss |
| 02 May 2024 16:00 | -1.42 | -2.30 | -61.9% | Miss |
| 07 Feb 2024 16:00 | -1.76 | -1.54 | +12.7% | Beat |
| 07 Nov 2023 16:00 | -2.25 | -2.88 | -28.1% | Miss |
| 05 Sep 2023 16:00 | -2.60 | -2.16 | +16.8% | Beat |
| 27 Apr 2023 16:00 | -2.62 | -1.98 | +24.3% | Beat |
| 16 Feb 2023 16:00 | -2.55 | -3.70 | -45.3% | Miss |
| 02 Nov 2022 16:00 | -2.53 | -3.03 | -19.6% | Miss |
| 10 Aug 2022 16:00 | -2.25 | -1.46 | +35.2% | Beat |
| 11 May 2022 16:00 | -1.99 | -2.21 | -11.1% | Miss |
| 02 Mar 2022 16:00 | -2.33 | -1.87 | +19.8% | Beat |
| 10 Nov 2021 16:00 | -2.29 | -1.47 | +35.8% | Beat |
| 25 Aug 2021 16:00 | -2.23 | -2.50 | -12.2% | Miss |
| 27 May 2021 16:00 | -1.90 | -1.17 | +38.4% | Beat |
| 10 Mar 2021 16:00 | -1.55 | -2.64 | -69.9% | Miss |
| 11 Nov 2020 16:00 | -1.59 | -2.31 | -45.6% | Miss |
| 27 Aug 2020 16:00 | -1.41 | -1.97 | -39.4% | Miss |
| 19 May 2020 16:00 | -1.30 | -1.32 | -1.6% | Miss |
| 01 Apr 2020 17:00 | -1.20 | -1.67 | -39.2% | Miss |
| 18 Nov 2019 16:00 | -1.16 | -0.53 | +54.4% | Beat |
| 28 Aug 2019 16:00 | -1.20 | -1.25 | -4.4% | Miss |
| 30 May 2019 16:00 | -1.02 | -1.24 | -21.2% | Miss |
| 03 Apr 2019 16:00 | -1.01 | -0.76 | +24.6% | Beat |
| 28 Nov 2018 16:00 | -1.02 | -0.81 | +20.8% | Beat |
| 29 Aug 2018 16:00 | -0.86 | -0.55 | +36.0% | Beat |
| 30 May 2018 16:00 | -0.74 | -1.07 | -45.2% | Miss |
| 28 Mar 2018 16:00 | -0.80 | -0.92 | -14.3% | Miss |
| 16 Nov 2017 16:00 | -0.73 | -1.04 | -42.2% | Miss |
| 18 Aug 2017 07:00 | -0.74 | -0.94 | -27.1% | Miss |
| 23 May 2017 16:00 | -0.70 | -0.78 | -11.7% | Miss |
| 22 Mar 2017 16:00 | -0.67 | -0.51 | +23.7% | Beat |
| 30 Nov 2016 16:00 | -0.60 | -0.72 | -19.9% | Miss |
| 31 Aug 2016 16:00 | -0.58 | -0.53 | +8.4% | Beat |
| 14 Apr 2016 16:00 | -0.28 | -0.52 | -87.1% | Miss |
| 12 Nov 2015 07:00 | -0.53 | -0.30 | +43.5% | Beat |
| 24 Aug 2015 17:00 | -0.38 | -0.63 | -66.7% | Miss |
| 18 May 2015 16:00 | -0.24 | 0.06 | +124.8% | Beat |
| 25 Mar 2015 16:00 | -0.15 | -0.64 | -338.4% | Miss |
Annual results · EUR
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 720.1M | +98.0% | -228M | -31.7% | -3.76 | +42.4% | 45.4M |
| 2024 | 363.6M | +36.3% | -378.1M | -104.0% | -6.53 | +23.6% | -307.6M |
| 2023 | 266.7M | +421.2% | -481.4M | -180.5% | -8.55 | +17.8% | -469.8M |
| 2022 | 51.2M | — | -583.2M | -1,139.6% | -10.40 | — | -510.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 252.55 | 275.33 | 248.31 | 273.51 | +8.85% | 7,249,261 | |
| Oct 2026 | 228.03 | 255.61 | 219.52 | 251.27 | +10.29% | 15,344,200 | |
| Sep 2026 | 261.65 | 272.47 | 220.23 | 227.83 | -13.39% | 18,756,600 | |
| Aug 2026 | 244.68 | 268.98 | 239.56 | 263.04 | +7.84% | 10,895,700 | |
| Jul 2026 | 267.51 | 282.15 | 243.30 | 243.91 | -8.55% | 11,375,400 | |
| Jun 2026 | 224.11 | 271.89 | 203.80 | 266.72 | +19.01% | 19,579,800 | |
| May 2026 | 229.38 | 250.27 | 218.08 | 224.11 | -2.30% | 12,063,900 | |
| Apr 2026 | 231.50 | 250.74 | 216.22 | 229.38 | +0.28% | 17,015,200 | |
| Mar 2026 | 235.18 | 248.60 | 212.60 | 228.73 | -2.04% | 12,594,300 | |
| Feb 2026 | 225.67 | 237.00 | 211.00 | 233.50 | +3.27% | 14,868,400 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH and ... (opens in a new tab) GuruFocus.com · 12 Nov 2026 23:08
- Ascendis Pharma earnings analysis: questions answered and next catalysts (opens in a new tab) Investing.com · 12 Nov 2026 20:55
- Ascendis Pharma A/S Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 12 Nov 2026 17:15
- Ascendis (ASND) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 12 Nov 2026 15:29
- Ascendis Pharma Reports Third Quarter 2026 Financial Results (opens in a new tab) 12 Nov 2026 12:30
- Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 12 Nov 2026 11:59
- Ascendis Pharma Q3 Adj. EPS $1.97 Beats $1.13 Estimate, Sales $425.432M Beat $417.230M Estimate (opens in a new tab) Benzinga · 12 Nov 2026 08:36
- Ascendis Pharma (NASDAQ:ASND) Offers Strong Growth With a Quality Technical Setup (opens in a new tab) ChartMill · 11 Nov 2026 09:31
- Ascendis Pharma to Participate in the Jefferies London Healthcare Conference (opens in a new tab) 10 Nov 2026 21:01
- Ascendis Pharma Says COMP Of EMA Adopts Positive Opinion Recommending Maintenance Of Orphan Medicinal Product Designation For Once-Weekly TransCon CNP As Treatment For Achondroplasia In Children (opens in a new tab) Benzinga · 06 Nov 2026 09:02
- Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 (opens in a new tab) 05 Nov 2026 21:01
- ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug (opens in a new tab) Stocktwits · 16 Oct 2026 21:30
- Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia (opens in a new tab) MT Newswires · 16 Oct 2026 13:58
- This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase (opens in a new tab) Insider Monkey · 05 Oct 2026 14:47
- Ascendis Pharma (ASND) Authorizes $400M Share Buyback (opens in a new tab) Insider Monkey · 21 Sep 2026 03:55
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 267.07 USD
- Market cap
- 17.6B
- Exchange
- NasdaqGS
- Country
- Denmark
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 10.1 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.6 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 6.8 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -1.7× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 20.47× | Fair | 30.56× |
| P/E (forward) | 23.77× | Fair | 14.16× |
| Price / book | -89.61× | Weak | 3.5× |
| Price / sales | 16.78× | Weak | 3.33× |
| EV / EBITDA | 63.26× | Weak | 11.19× |
| Free cash flow yield | 0.1% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 91.3% | Good | 54.9% |
| Operating margin | 24.7% | Good | 5.8% |
| Net margin | 70.8% | Good | 1.2% |
| Return on equity | 118.8% | Good | 4.4% |
| Return on assets | 9.6% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 141.4% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.31× | Good | 0.4× |
| Net debt / EBITDA | -1.37× | Good | 1.46× |
| Interest cover | -1.69× | Weak | 2.17× |
| Current ratio | 2.99× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow ASND and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.